A medication given to diabetics to improve their body’s sensitivity to insulin also appears to slow the thickening of their artery walls, according to a study posted online today by JAMA. The study is being released early to coincide with its presentation at the American Heart Association Scientific Session. It will be published in the December 6 print issue of JAMA.
DSM is continuing to build its personalised nutrition capabilities with its venturing arm making a ?2m investment in IntegraGen, and a collaboration with the French biotech to apply its genetic tests to weight management products.
Abdominal obesity increased more than 65 percent among boys and almost 70 percent among girls between 1988 and 2004. The finding of growing girth is significant because abdominal obesity has emerged as a better predictor of cardiovascular disease and type 2 diabetes risk than the more commonly used Body Mass Index, a weight-to-height ratio that can sometimes be misleading.
Researchers have used a single compound to increase the lifespan of obese mice, and found that the drug reversed nearly all of the changes in gene expression patterns found in mice on high calorie diets–some of which are associated with diabetes, heart disease, and other significant diseases related to obesity. The research, led by investigators at Harvard Medical School and the National Institute on Aging, is the first time that the small molecule resveratrol has been shown to offer survival benefits in a mammal. The study is reported in the November 1 advanced online edition of Nature.
A new obesity pill that helps to control blood sugar levels could treat patients with type 2 diabetes, researchers say. They found that the Sanofi-Aventis drug Acomplia, which is also known as rimonabant, also reduced risk factors for heart disease in patients with type 2 diabetes who had not responded to standard treatments.
According to a review of clinical trials, benefits of pioglitazone for type 2 diabetes is unclear. Marketed by Takeda Pharmaceuticals and Eli Lilly & Co. as Actos, pioglitazone belongs to a class of drugs called thiazolidinediones that work by increasing the body’s sensitivity to insulin, to better control patients’ blood sugar. It is used alone or in combination with other drugs if diabetes can’t be controlled by diet and exercise.
Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark?s DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the U.S. anti-trust agencies under the HSR Act.
Data presented at the European Association for the Study of Diabetes (EASD) 42nd Conference in Copenhagen showed NovoMix? 30 (biphasic insulin aspart) to have comparable efficacy to basal-bolus combination therapy, with a similar safety profile in patients previously treated with oral antidiabetic therapy. These findings follow on from the European Commission?s recent decision to approve NovoMix? 30 as the first premixed insulin suitable for once-daily initiation and subsequent intensification of treatment, if needed. The data also confirm the position of NovoMix? 30 as an appropriate treatment choice for patients who prefer a convenient, effective once or twice-daily insulin therapy.
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
Diet plays a key role in controlling your blood sugar. A healthy-eating plan tailored to your needs will do that and more. Majority of people affected with diabetes are overweight or obese. In fact, your risk of getting diabetes increases the more weight you put on.